Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.

ABSTRACT: The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization^1-3, with more in the pipeline^4-7. Furthermore, multiple vaccine constructs have shown promise⁸, including two with ~95% protective efficacy against COVID-19^9,10. However, these interventions were directed toward the initial SARS-CoV-2 that emerged in 2019. The recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK¹¹ and B.1.351 in South Africa¹² is of concern because of their purported ease of transmission and extensive mutations in

SUBMITTER: Wang P 

PROVIDER: S-EPMC7852271 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature